First read for a new ticker takes about 20–30 seconds while we build the analysis from the latest fundamentals, estimates, and intelligence. It's saved after this, so future visits are instant.
★ Analysts see FY2027 revenue reaching $865.7B — +0.9% growth in a single year.
What Moves the Stock
1Leqembi commercial uptake metrics: quarterly prescription volumes, reimbursement coverage expansion (Medicare CMS coverage critical), infusion center capacity buildout, and patient diagnosis rates through biomarker testing
2Lenvima lifecycle management: combination therapy approvals with checkpoint inhibitors (Keytruda partnership revenues), label expansions in additional tumor types, and competitive positioning against TKI alternatives
3Pipeline clinical trial readouts: particularly MORAb-202 (folate receptor alpha ADC) Phase 2 data in ovarian cancer, and next-generation Alzheimer's assets beyond Leqembi
4Regulatory decisions and reimbursement: FDA/EMA approvals for pipeline assets, pricing negotiations in Japan under biennial drug price revisions, and China NRDL (National Reimbursement Drug List) inclusion for key products
5Oncology franchise (~45% of revenue): Lenvima (lenvatinib) for thyroid, renal, hepatocellular carcinoma; partnerships with Merck on combination therapies